Differential diagnosis of serous papillary carcinoma of the gynaecological tract and basal breast carcinoma: An immunohistochemical approach

Pathology

Volumn 42, Issue 6, 2010, Pages 534-539

  Armes, Jane E ^a   Bowlay, Greg ^a   Lourie, Rohan ^a   Venter, Deon J ^a   Price, Gareth ^a  

^a MATER HOSPITAL   (Australia)

Author keywords

Basal breast carcinoma; Breast; Gynaecological; Immunohistochemistry; Serous papillary carcinoma of gynaecological tract

Indexed keywords

EID: 77956892613     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.3109/00313025.2010.508793     Document Type: Article

References (30)

1. Lakhani SR, Manek S, Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004; 10: 2473-2481
2. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008; 26: 2568-2581
3. Janatova M, Zikan M, Dundr P, Matous B, Pohlreich P. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. Hum Mutat 2005; 25: 319.
4. Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO. Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 2008; 39: 857-865
5. Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2006; 16 (Suppl 1): 166-171
6. Page DL, Anderson TJ. Diagnostic Histopathology of the Breast. Edinburgh: Churchill Livingstone, 1987.
7. Tavassoli FA, Devilee P. WHO Classification of Tumours; Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press, 2003.
8. Silverberg SG. Histopathologic grading of ovarian carcinoma: a review and proposal. Int J Gynecol Pathol 2000; 19: 7-15.
9. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145
10. Armes JE, Trute L, White D, et al. Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 1999; 59: 2011-2017
11. Cathro HP, Stoler MH. Expression of cytokeratins 7 and 20 in ovarian neoplasia. Am J Clin Pathol 2002; 117: 944-951
12. O'Neill CJ, Deavers MT, Malpica A, Foster H, McGluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high grade neoplasms. Am J Surg Pathol 2005; 29: 1034-1041
13. Tornos C, Soslow R, Chen S, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol 2005; 29: 1482-1489
14. Scharnhorst V, van der Eb AJ, Jochemsen AG. WT1 proteins: functions in growth and differentiation. Gene 2001; 273: 141-161
15. Schorge JO, Miller YB, Qi LJ, et al. Genetic alterations of the WT1 gene in papillary serous carcinoma of the peritoneum. Gynecol Oncol 2000; 76: 369-372
16. Shimizu M, Toki T, Takagi Y, Konishi I, Fujii S. Immunohistochemical detection of the Wilms' tumor gene (WT1) in epithelial ovarian tumors. Int J Gynecol Pathol 2000; 19: 158-163
17. Andikyan V, Taylor HS. WT1 represses HOX gene expression in the regulation of gynecologic tumor histologic type. J Cell Mol Med 2009; 13: 4522-4531
18. Kommoss F, Pfisterer J, Thome M, Schafer W, Sauerbrei W, Pfleiderer A. Steroid receptors in ovarian carcinoma: immunohistochemical determination may lead to new aspects. Gynecol Oncol 1992; 47: 317-322
19. Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S, Tanwanich S. Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer 2009; 19: 620-627
20. Burges A, Bruning A, Dannenmann C, et al. Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary. Arch Gynecol Obstet 2009; 281: 511-517
21. Liu JF, Hirsch MS, Lee H, Matulonis UA. Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol 2009; 115: 401-406
22. Cho EY, Choi YL, Chae SW, Sohn JH, Ahn GH. Relationship between p53-associated proteins and estrogen receptor status in ovarian serous neoplasms. Int J Gynecol Cancer 2006; 16: 1000-1006
23. Lau KM, Mok SC, Ho SM. Expression of human estrogen receptoralpha and-beta, progesterone receptor, and androgen receptor mRNA in normal and malignant ovarian epithelial cells. Proc Natl Acad Sci USA 1999; 96: 5722-5727
24. Korsching E, Jeffrey SS, MeinerzW, Decker T, Boecker W, Buerger H. Basal carcinoma of the breast revisited: an old entity with new interpretations. J Clin Pathol 2008; 61: 553-560
25. Comin CE, Saieva C, Messerini L. h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 2007; 31: 1139-1148
26. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study. Mod Pathol 2006; 19: 34-48.
27. Armes JE, Lourie R, de Silva M, et al. Abnormalities of the RB1 pathway in ovarian serous papillary carcinoma as determined by overexpression of the p16(INK4A) protein. Int J Gynecol Pathol 2005; 24: 363-368
28. O'Neill CJ, McBride HA, Connolly LE, Deavers MT, Malpica A, McCluggage WG. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour. Histopathology 2007; 50: 773-779
29. Subhawong AP, Subhawong T, Nassar H, et al. Most basal-like breast carcinomas demonstrate the same Rb-/p16+immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically. Am J Surg Pathol 2009; 33: 163-175
30. Herschkowitz JI, He X, Fan C, Perou CM. The functional loss of the retinoblastoma tumour suppressor is a common event in basallike and luminal B breast carcinomas. Breast Cancer Res 2008; 10: R75.